Tau aggregation and its interplay with amyloid-β
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Neurofibrillary tangles and amyloid plaques constitute the hallmark brain lesions of Alzheimer's disease (AD) patients. Tangles are composed of fibrillar aggregates of the microtubule-associated protein tau, and plaques comprise fibrillar forms of a proteolytic cleavage product, amyloid-β (Aβ). Although plaques and tangles are the end-stage lesions in AD, small oligomers of Aβ and tau are now receiving increased attention as they are shown to correlate best with neurotoxicity. One key question of debate, however, is which of these pathologies appears first and hence is upstream in the pathocascade. Studies suggest that there is an intense crosstalk between the two molecules and, based on work in animal models, there is increasing evidence that Aβ, at least in part, exerts its toxicity via tau, with the Src kinase Fyn playing a crucial role in this process. In other experimental paradigms, Aβ and tau have been found to exert both separate and synergistic modes of toxicity. The challenge, however, is to integrate these different scenarios into a coherent picture. Furthermore, the ability of therapeutic interventions targeting just one of these molecules, to successfully neutralize the toxicity of the other, needs to be ascertained to improve current therapeutic strategies, such as immunotherapy, for the treatment of AD. Although this article is not intended to provide a comprehensive review of the currently pursued therapeutic strategies, we will discuss what has been achieved by immunotherapy and, in particular, how the inherent limitations of this approach can possibly be overcome by novel strategies that involve single-chain antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51],”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of glial cells may provide a link between the initial Aβ aggregation and the later development of tau aggregates,40”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“It is evident that crosstalk between Aβ and tau can significantly influence toxicity; increased Aβ production results in NFT formation in FAD and Down Syndrome, while there is also evidence to show that tau increases Aβ-associated toxicity (particularly synaptotoxcity), suggesting that the presence of both pathological features are important to replicate the toxicity that occurs in human AD [106].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“1 3 There is considerable debate regarding which Aβ species is the most neurotoxic, with increasing evidence suggesting that it is the small molecular weight oligomers that correlate best with disease [8, 52, 62, 67].”
BackgroundRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Furthermore, more than 20 pathogenic mutations have been identified in APP and several of these, including the V717I ‘London’ mutation [29], the V717F ‘Indiana’ mutation [66], the K670D/M671L ‘Swedish’ mutation [65] and the E693G ‘Arctic’ mutation [69], have been expressed in transgenic mice.”
BackgroundTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · cited 2×
“Evidently, no mouse model is capable of fully recapitulating the neuropathological spectrum of the disease [72].”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · cited 1×
“connected brain regions [15].”
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Cited by
Items 101–200 of 360
Hang, Z., Lei, T., Zeng, Z., Cai, S., Bi, W., & Du, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112343 · Cited by 47
Monda, A., Torre, M. E. L., Messina, A., Maio, G. D., Monda, V., Moscatelli, F., Stefano, M. D., Marra, M. L., di Padova, M., Dipace, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1425816 · Cited by 51
Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease
Lan, Z., Chen, Y., Jin, J., Xu, Y., & Zhu, X. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.821002 · Cited by 48
“Aβ exerts its toxicity at least in part through tau and the Aβdependent pathologies can be greatly amplified by tau expression (Bloom, 2014; Nisbet et al., 2015).”
BackgroundZhang, J., Konsmo, A., Sandberg, A., Wu, X., Nyström, S., Obermüller, U., Wegenast‐Braun, B. M., Konradsson, P., Lindgren, M., & Hammarström, P. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01681 · Cited by 47
Timmers, M., Tesseur, I., Bogert, J., Zetterberg, H., Blennow, K., Börjesson-Hanson, A., Baquero, M., Boada, M., Randolph, C., Tritsmans, L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.016 · Cited by 42
“Recent preclinical studies have highlighted several possible pathways by which Aβ could directly and indirectly influence the levels of tau, induce hyperphosphorylation of tau and the formation of neurofibrillary tangles (Gotz et al., 2001; Nisbet et al., 2015).”
BackgroundCorsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Exosomal and vesicle‐free tau seeds—propagation and convergence in endolysosomal permeabilization
Polanco, J. C., & Götz, J. (2022) · The FEBS Journal · doi:10.1111/febs.16055 · Cited by 42
Self-citationEndoplasmic Reticulum Stress Signaling Pathways: Activation and Diseases
Zheng, Z. J., Shang, Y., Tao, J., Zhang, J., & Sha, B. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190621103145 · Cited by 46
Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Bjorkli, C., Sandvig, A., & Sandvig, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00272 · Cited by 48
“Autophagy: late stages of autophagy is disrupted in AD patients, as an accumulation of autophagic vesicles can be observed in dystrophic neurites (Komatsu et al., 2006), and are observed prior to extracellular Aβ deposition (Mehrpour et al., 2010; Nixon and Yang, 2011).”
BackgroundHoque, A., Hossain, M. I., Ameen, S. S., Ang, C., Williamson, N. A., Ng, D. C. H., Chüeh, A. C., Roulston, C. L., & Cheng, H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.009 · Cited by 43
“For the latest advances in this area of research, readers are referred to several excellent reviews by Parsons and Raymond (Parsons and Raymond, 2014), Nisbet, et al. (Nisbet et al., 2015) and Nygaard, et al. (Nygaard et al., 2014).”
BackgroundAlzheimer’s disease pathological lesions activate the spleen tyrosine kinase
Schweig, J. E., Yao, H., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Mouzon, B., Crawford, F., Mullan, M., & Paris, D. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0472-2 · Cited by 40
“Tau and Aβ have been proposed to synergistically contribute to the pathobiology of AD [25].”
Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform
Kolaj, I., Imindu Liyanage, S., & Weaver, D. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.001 · Cited by 39
“However, these efforts have yet to yield an effective therapy, possibly as tau's place in AD etiology and its synergism with Aβ remain ambiguous (Bakota and Brandt, 2016; Khan and Bloom, 2016; Nisbet et al., 2015).”
BackgroundXu, A., Yang, Y., Sun, Y., & Zhang, C. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.241471 · Cited by 39
“Emerging data have suggested that tau plays a critical role in synaptic plasticity via binding related partners (Ittner et al., 2010; Morris et al., 2011; Nisbet et al., 2015; Regan et al., 2016).”
Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration?
Shirooie, S., Nabavi, S. F., Dehpour, A. R., Belwal, T., Habtemariam, S., Argüelles, S., Sureda, A., Daglia, M., Tomczyk, M., Sobarzo‐Sánchez, E., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.004 · Cited by 38
Weller, R. O., Hawkes, C. A., Carare, R. O., & Hardy, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1416-1 · Cited by 37
Dementia-like pathology in type-2 diabetes: A novel microRNA mechanism
Kalani, A., Chaturvedi, P., Maldonado, C. J., Bauer, P. M., Joshua, I. G., Tyagi, S. C., & Tyagi, N. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.02.005 · Cited by 38
“Tau phosphorylation alongwith Aβ tangles are important mediators of neurotoxicity and are associated with cognitive deficits (Nisbet et al., 2015).”
Lippi, S. L. P., Smith, M. L., & Flinn, J. M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00382 · Cited by 36
“Amyloid increases tau phosphorylation (Lloret et al., 2011; Nisbet et al., 2015),”
Oumata, N., Lu, K., Teng, Y., Cavé, C., Yu, P., Galons, H., & Roques, B. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114578 · Cited by 38
Yeast buddies helping to unravel the complexity of neurodegenerative disorders
Fruhmann, G., Seynnaeve, D., Zheng, J., Ven, K., Molenberghs, S., Wilms, T., Liu, B., Winderickx, J., & Franssens, V. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.05.002 · Cited by 40
Jana, A. K., Batkulwar, K., Kulkarni, M. J., & Sengupta, N. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp05041g · Cited by 37
The vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 43
Moawad, M. H. E. D., Serag, I., Alkhawaldeh, I. M., Abbas, A., Sharaf, A., Alsalah, S., Sadeq, M. A., Shalaby, M. M. M., Hefnawy, M. T., Abouzid, M., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04468-y · Cited by 46
“Moreover, reports indicate that a decline in proteasome activity brought on by aging may facilitate the deposition of Aβ and tau [96, 97].”
Viswanathan, G. K., Paul, A., Gazit, E., & Segal, D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00242 · Cited by 33
“The two neuropathological hallmarks of AD are the amyloidogenic deposition of extra-cellular Amyloid β (Aβ peptide) plaques and intra-cellular tangles of the Tau protein (Nisbet et al., 2015).”
BackgroundKaur, A., Shuaib, S., Goyal, D., & Goyal, B. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp04775a · Cited by 35
Taylor, J. L., Hambro, B. C., Strossman, N. D., Bhatt, P., Hernandez, B., Ashford, J. W., Cheng, J. J., Iv, M., Adamson, M. M., Lazzeroni, L. C., et al. (2019) · BMC Neurology · doi:10.1186/s12883-019-1552-7 · Cited by 38
Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders
Ranjan, A. K., & Gulati, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063146 · Cited by 37
Intestinal Flora Affect Alzheimer's Disease by Regulating Endogenous Hormones
Wu, Y., Hang, Z., Tong, L., & Du, H. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03784-w · Cited by 35
“The main pathological feature of AD is neurofibrillary tangles, which result from hyperphosphorylation of tau protein in neurons and abnormal accumulation of amyloid-beta (Aβ) outside senile plaques [4, 5].”
BackgroundKumaran, K. R., Yunusa, S., Perimal, E. K., Wahab, H. A., Müller, C. P., & Hassan, Z. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220666 · Cited by 42
Liu, S., Xu, L., Shen, Y., Wang, L., Lai, X.-X., & Hu, H. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117031 · Cited by 41
Tau protein aggregation: Key features to improve drug discovery screening
Giovannini, J., Smeralda, W., Jouanne, M., Santos, J. S. O., Catto, M., & Voisin‐Chiret, A. S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.009 · Cited by 35
Yang, M., Chen, S.-C., Lin, Y., Lee, Y., Huang, M., Chen, K., Wu, H., Lin, P., Gozes, I., & Tyan, Y. (2019) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2018.11.009 · Cited by 55
Beta‐amyloid 1‐42 monomers, but not oligomers, produce PHF ‐like conformation of Tau protein
Manassero, G., Guglielmotto, M., Zamfir, R., Borghi, R., Colombo, L., Salmona, M., Perry, G., Odetti, P., Arancio, O., Tamagno, E., et al. (2016) · Aging Cell · doi:10.1111/acel.12500 · Cited by 32
“In previous reports, the capability of A b 1-42 to induce Tau aggregation was studied in mice expressing mutant human Tau, models of tauopathies (Lewis et al. , 2001; Oddo et al. , 2006; Rhein et al. , 2009; Nisbet et al. , 2015).”
Laser Emission of Thioflavin T Uncovers Protein Aggregation in Amyloid Nucleation Phase
Hańczyc, P., & Fita, P. (2021) · ACS Photonics · doi:10.1021/acsphotonics.1c00082 · Cited by 34
Metabolite Clearance During Wakefulness and Sleep
Hladky, S. B., & Barrand, M. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_37 · Cited by 39
“…it is not known which form of Aβ is responsible for the toxic effects ascribed to it, current evidence appears to suggest that within the parenchyma the main culprits are the oligomers (Lambert et al. 1998; Zerbinatti et al. 2004; Haass and Selkoe 2007; Nisbet et al. 2015; McIntee et al. 2016).”
Current anti-Alzheimer’s disease effect of natural products and their principal targets
Zhu, Y., Peng, L., Hu, J., Chen, Y., & Chen, F. (2019) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2019.03.1105 · Cited by 33
“Both the abnormal activation of protein kinases and the down-regulation of phosphorylase activity leads to hyperphosphorylation of tau (Gu et al., 2010; Nisbet et al., 2015).”
BackgroundSaliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
Marksteiner, J., Defrancesco, M., & Humpel, C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1014305 · Cited by 41
“Tau is a microtubule-associated protein and physiologically stabilizes and regulates axonal transport (Liu and Götz, 2013; Spillantini and Goedert, 2013; Nisbet et al., 2015; Wang and Mandelkow, 2016).”
BackgroundDetection and Imaging of Aβ1‐42 and Tau Fibrils by Redesigned Fluorescent X‐34 Analogues
Zhang, J., Sandberg, A., Konsmo, A., Wu, X., Nyström, S., Nilsson, K. P. R., Konradsson, P., LeVine, H., Lindgren, M., & Hammarström, P. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800501 · Cited by 31
Michno, W., Wehrli, P. M., Meier, S. R., Sehlin, D., Syvänen, S., Zetterberg, H., Blennow, K., & Hanrieder, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14888 · Cited by 29
“3xTg, also including a presenilin-1 mutation) could potentially be more relevant due to the potential interplay between Aβ and tau (Nisbet et al. 2015).”
BackgroundMicroRNA Networks in Cognition and Dementia
Blount, G. S., Coursey, L., & Kocerha, J. (2022) · Cells · doi:10.3390/cells11121882 · Cited by 31
Yavari, M., Kalupahana, N. S., Harris, B. N., Ramalingam, L., Zu, Y., Kahathuduwa, C. N., & Moustaïd‐Moussa, N. (2025) · Nutrients · doi:10.3390/nu17071203 · Cited by 30
“This benefit of DHA is also reported in a mouse model of AD, and the inhibition of tau phosphorylation was associated with improved animal cognitive performance [180,181].”
Li, Y., Ding, R., Ren, X., Wen, G., Dong, Z., Yao, H., Tan, Y., Yu, H. Q., Wang, X., Zhan, X., et al. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.08.023 · Cited by 29
Townsend, D. J., Mala, B., Hughes, E., Hussain, R., Siligardi, G., Fullwood, N. J., & Middleton, D. A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00154 · Cited by 29
Petrov, D., Luque, M., Pedrós, I., Ettcheto, M., Abad, S., Pallàs, M., Verdaguer, E., Auladell, C., Folch, J., & Camins, A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9522-6 · Cited by 30
Selvaraj, P., Wen, J., Tanaka, M., & Zhang, Y. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.6226 · Cited by 29
Acetylation of Aβ42 at Lysine 16 Disrupts Amyloid Formation
Adhikari, R., Yang, M., Saikia, N., Dutta, C., Alharbi, W. F. A., Shan, Z. J., Pandey, R., & Tiwari, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00069 · Cited by 29
Kilinc, D., Vreulx, A.-C., Mendes, T., Flaig, A., Coelho, D. M., Verschoore, M., Demiautte, F., Amouyel, P., Bank, N.-C. B., Eysert, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa139 · Cited by 37
“…worldwide, is characterized by two types of brain lesions: (i) neurofibrillary degeneration due to the intracellular aggregation of abnormally hyperphosphorylated tau protein and (ii) amyloid plaques resulting from the extracellular accumulation of amyloid b (Ab) peptides (Nisbet et al., 2015).”
BackgroundMultifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers
Ansari, M. A., Tripathi, T., Venkidasamy, B., Monziani, A., Rajakumar, G., Alomary, M. N., Alyahya, S. A., Onimus, O., D’souza, N., Barkat, M. A., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03730-z · Cited by 32
“During the development of AD, Tau uncouples from microtubules and aggregates into tangles thereby inhibiting transport and resulting in microtubule disassembly [12].”
Chen, C., Yan, Z., Ma, Y., & Ding, H. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00485 · Cited by 28
Ravichandran, S., Snyder, P. J., Alber, J., Murchison, C., Chaby, L. E., Jeromin, A., & Arthur, E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01668-5 · Cited by 31
“Moreover, studies have also suggested that neuroinflammation might be the connecting link between initial Aβ pathology and the subsequent development of NFTs [46–48].”
Lassen, P. S., Thygesen, C., Larsen, M. R., & Kempf, S. J. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.04.003 · Cited by 26
Type 1 Interleukin-4 Signaling Obliterates Mouse Astroglia in vivo but Not in vitro
Mashkaryan, V., Siddiqui, T., Popova, S. D., Coşacak, M. İ., Bhattarai, P., Brandt, K., Govindarajan, N., Petzold, A., Reinhardt, S., Dahl, A., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00114 · Cited by 28
“…the disease, yet other cellular paradigms such as neurogenesis could be involved in manifestation of AD phenotypes (Amor et al., 2010; Rodriguez and Verkhratsky, 2011; Heneka et al., 2013; Nisbet et al., 2015; De Strooper and Karran, 2016; Dzamba et al., 2016; Scheltens et al., 2016; Kizil, 2018).”
BackgroundSingh, K., Kaur, A., Goyal, D., & Goyal, B. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp02601e · Cited by 26
Neuronal plasticity and its role in Alzheimer’s disease and Parkinson’s disease
Jahan, I., Harun‐Ur‐Rashid, M., Islam, M. A., Sharmin, F., Jaouni, S. K. A., Kaki, A. M., & Selim, S. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01019 · Cited by 35
“Tau tangles, or neurofibrillary tangles, are intracellular aggregates of hyperphosphorylated tau protein (Nisbet et al., 2015).”
αT-catenin in restricted brain cell types and its potential connection to autism
Folmsbee, S. S., Wilcox, D. R., Tyberghein, K., Bleser, P. D., Tourtellotte, W. G., van Hengel, J., Roy, F. M. V., & Gottardi, C. J. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0017-9 · Cited by 25
“Because we did not detect αT-cat in neurons of the cerebral cortex, and αT-cat KO mice demonstrate no overt neurologic dysfunction, we suspect there is no direct neuronal link of αT-cat dysfunction to the established, neuronal etiologies of ASD, or even AD, such as neurofibrillary tangles or amyloid plaques [49].”
BackgroundSajad, M., Kumar, R., & Thakur, S. C. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.04.009 · Cited by 28
“Hyperphosphorylation of tau also leads to the binding of p-tau to Fyn kinase, resulting in the movement of p-tau to the neurons of dendritic regions (Nisbet et al., 2015).”
BackgroundUbiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins
Braun, R. J. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00008 · Cited by 27
“Similarly, AD-associated mutations in the β-amyloid precursor protein (APP) or the γ-secretase components presenilin 1 or 2, which are pivotally involved in β-amyloid generation from APP, do also not fully recapitulate the key pathological events of AD (Nisbet et al., 2015).”
BackgroundBrighi, C., Cordella, F., Chiriatti, L., Soloperto, A., & Angelantonio, S. D. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00655 · Cited by 26
Sirtuins as Modifiers of Huntington's Disease (HD) Pathology
Neo, S. H., & Tang, B. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.013 · Cited by 25
Zhang, H., Wang, H., Gao, F., Yang, J. Y., Xu, Y., Fu, Y., Cai, M., Zhang, X., Yang, Q., Tong, K., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.06.020 · Cited by 24
You, Y., Hersh, S. W., Aslebagh, R., Shaffer, S. A., Ikezu, S., Mez, J., Lunetta, K. L., Logue, M. W., Farrer, L. A., & Ikezu, T. (2022) · Aging Cell · doi:10.1111/acel.13617 · Cited by 20
Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A. C., DeGrado, W. F., & Condello, C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01298-0 · Cited by 23
“As tau is thought to interact with Aβ in AD [4], changes in tau isoform ratios and phosphorylation via Chr21-associated proteins DYRK1A [66, 67] and RCAN1 [68] could also impact Aβ plaque composition.”
BackgroundHojjati, S. H., Feiz, F., Ozoria, S., Razlighi, Q. R., & Initiative, F. T. A. D. N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210419 · Cited by 25
“For instance, some studies have shown preliminary evidence that mild neuroinflammation might be the missing but key factor in the A (cid:2) and tau relationship [63–69].”
Yang, X., Yang, G., Yan, B., Xie, Y., Zhou, M., Wu, Y., Yao, L., Qiu, X., Yan, F., Chen, Y., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10687 · Cited by 25
“To date, the intricate etiology of the development of AD has remained to be fully elucidated, but there is evidence that both the microtu‐ bule‐associated protein tau and amyloid‐β (Aβ) exert complex and synergistic effects contributing to the hypometabolism and symptomatology of AD (4,5).”
BackgroundTransfer of Tumor-Bearing Mice Intestinal Flora Can Ameliorate Cognition in Alzheimer’s Disease Mice
Hang, Z., Cai, S., Lei, T., Zhang, X., Xiao, Z., Wang, D., Li, Y., Bi, W., Yang, Y., Deng, S., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215495 · Cited by 24
“All rights reserved. formation [1].”
Selvı, Y., Gergerlioğlu, H. S., Akbaba, N., Oz, M., Kandeğer, A., Demir, E. A., Yerlikaya, F. H., & Atalık, K. E. N. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.63 · Cited by 25
“The elevated deposition of Aβ and tau proteins is characteristically considered to be neuropathological in AD (40,41).”
BackgroundKaur, A., Goyal, D., & Goyal, B. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp04672h · Cited by 22
Li, W., Jin, L., Li, Y.-P., Feng, Q., Ren, L., Wang, F., & Bo, G.-J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.239448 · Cited by 24
“…by progressive deterioration of memory and cognitive dysfunction (Scheltens et al., 2016) caused by neural loss and degeneration, extra-cellular precipitation of amyloid beta (Aβ), and intracellular tau hyperphosphorylation (Nisbet et al., 2015; Lewis and Dickson, 2016; Selkoe and Hardy, 2016).”
BackgroundSimulating the effect of formation of amyloid plaques on aggregation of tau protein
Kuznetsov, I. A., & Kuznetsov, A. V. (2018) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2018.0511 · Cited by 22
Ugbaja, S. C., Lawal, I. A., Kumalo, H. M., & Lawal, M. M. (2021) · Current Drug Targets · doi:10.2174/1389450122666210809100050 · Cited by 22
Hisama, F. M., Oshima, J., & Martin, G. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025882 · Cited by 23
“Aggregates of the hyperphosphorylated microtubule-associated protein tau (Nisbet et al. 2015) are often considered to be downstream pathological events, as is microglia-mediated neuroinflammation (Tang and Le 2015).”
BackgroundAichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00828-1 · Cited by 25
“Tau aggregates are also abundant in other neurodegenerative diseases such as frontotemporal dementia or Picks’ disease [4].”
BackgroundClarelli, F., Mascia, E., Santangelo, R., Mazzeo, S., Giacalone, G., Galimberti, D., Fusco, F., Zuffi, M., Fenoglio, C., Franceschi, M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160074 · Cited by 21
Pintana, H., Apaijai, N., Kerdphoo, S., Pratchayasakul, W., Sripetchwandee, J., Suntornsaratoon, P., Charoenphandhu, N., Chattipakorn, N., & Chattipakorn, S. C. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.06.041 · Cited by 24
“It has been proposed that the increasing of Aβ level and hyperphosphorylated tau (p-tau), are key pathogenic determinants of AD [23].”
Middelveen, M. J., Filush, K. R., Bandoski, C., Kasliwala, R. S., Melillo, A., Stricker, R. B., & Sapi, E. (2019) · Healthcare · doi:10.3390/healthcare7020070 · Cited by 24
“This tau alteration decreases its capacity to bind to microtubules, compromises microtubule stabilization and axonal transport, and increases tau self-assembly and aggregate formation [81,98].”
BackgroundJoseph, C. R. (2020) · Biomedicines · doi:10.3390/biomedicines8070228 · Cited by 20
Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease
Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 22
“Evidence also showed that Aβ can trigger tau hyperphosphorylation and Aβ toxicity is taudependent in the dendritic compartment of neurons [58, 59].”
BackgroundNon-conventional compounds with potential therapeutic effects against Alzheimer’s disease
de Castro, A. A., Soares, F. V., Pereira, A. F., Polisel, D. A., Caetano, M. S., Leal, D. H. S., da Cunha, E. F. F., Nepovimová, E., Kuča, K., & Ramalho, T. C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1608823 · Cited by 21
“A linkage between deposits and soluble oligomers of Aβ and progressive phosphorylation of the tau protein is an important topic for the substantiation of theories concerning the development and evolution of AD [66].”
BackgroundChatterjee, D., Jacob, R. S., Ray, S., Navalkar, A., Singh, N., Sengupta, S., Gadhe, L. G., Kadu, P., Datta, D., Paul, A., et al. (2022) · eLife · doi:10.7554/elife.73835 · Cited by 18
Arendash, G. W., Abulaban, H., Steen, S., Andel, R., Wang, Y., Bai, Y., Baranowski, R., McGarity, J., Scritsmier, L., Lin, X., et al. (2022) · Medicines · doi:10.3390/medicines9080042 · Cited by 21
“These small soluble aggregates are formed inside neurons, where they cause neuronal dysfunction and death [13–22].”
Doke, R. R., Lamkhade, G., Vinchurkar, K., & Singh, S. K. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00457 · Cited by 25
Conformational restraint as a strategy for navigating towards lysosomes
Liang, X., Cheng, J., Qin, S., Shao, L.-X., Huang, M., Wang, G., Han, Y., Han, F., & Li, X. (2018) · Chemical Communications · doi:10.1039/c8cc06155f · Cited by 21
Berry, B. J., Smith, A. S. T., Long, C. J., Martin, C., & Hickman, J. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00067 · Cited by 21
Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau
Zampar, S., & Wirths, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105191 · Cited by 18
“The common belief is that Aβ acts as a pathological trigger, with tau being the required executor [4,5].”
BackgroundHyperglycosylation is a metabolic driver of Alzheimer’s disease
Hawkinson, T. R., Liu, Z., Ribas, R. A., Medina, T., Nielsen, R. S., Clarke, H. A., Ma, X., Mueller, A. C., Plasencia, A. F., Sheer, A. L., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01538-4 · Cited by 26
“Recent research in AD has revealed a complex interplay between multiple pathological processes, including the functional diversity of microglia subtypes 18 , tau propagation 19 , amyloid-beta/tau crosstalk 20 , neuroinflammation 21 and lipid metabolism dysregulation 5 .”
Plexin-A4 mediates amyloid-β–induced tau pathology in Alzheimer’s disease animal model
Chung, S., Yang, J., Kim, H. J., Hwang, E. M., Lee, W., Suh, K. Y., Choi, H., & Mook‐Jung, I. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102075 · Cited by 20
“Previous studies have reported that interactions between Aβ and tau can amplify neurotoxicity and accelerate neurodegeneration (Nisbet et al., 2015; Rhein et al., 2009; Spires-Jones and Hyman, 2014).”
BackgroundDeletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01044-1 · Cited by 18
“and tau (Nisbet et al., 2015), characterized by the unique region-specific spread of tau and could”
BackgroundFrank, M., Ni, P., Jensen, M., & Gerstein, M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320510121 · Cited by 23
Bajracharya, R., Brici, D., Bodea, L., Janowicz, P. W., Götz, J., & Nisbet, R. M. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01147-0 · Cited by 20
“This makes tau an attractive therapeutic target [2].”
BackgroundSelf-citationMondal, P., Das, G., Khan, J., Pradhan, K., Mallesh, R., Saha, A., Jana, B., & Ghosh, S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00115 · Cited by 19
Effects of exercise on neuroinflammation in age-related neurodegenerative disorders
Su, Y., & Su, Z. (2025) · European journal of medical research · doi:10.1186/s40001-025-03165-3 · Cited by 26
“Researchers have found that microglia are activated beforehand and this leads to increased levels of tau protein phosphorylation, triggering the development of neurofibrillary tangles [65–67].”
Pharmacological intervention in oxidative stress as a therapeutic target in neurological disorders
Sharma, S., Advani, D., Das, A., Malhotra, N., Khosla, A., Arora, V., Jha, A., Yadav, M., Ambasta, R. K., & Kumar, P. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab064 · Cited by 19
Elias, A., Cummins, T. L., Lamb, F., Tyrrell, R., Doré, V., Williams, R., Rosenfeld, J. V., Hopwood, M., Villemagne, V. L., & Rowe, C. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190913 · Cited by 18
Moelgg, K., Jummun, F., & Humpel, C. (2021) · Biomolecules · doi:10.3390/biom11030434 · Cited by 19
“The causes of AD are yet unknown but at present the Aβ cascade, which is the most prominent hypothesis [2], is surrounded by more and more controversy [3,4].”
BackgroundVignon, A., Salvador-Prince, L., Lehmann, S., Perrier, V., & Torrent, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168769 · Cited by 19
“tau or Aβ species initiate the pathological process [30,31].”
BackgroundMoreno‐González, I., Edwards, G. A., Morales, R., Duran-Aniotz, C. A., Escobedo, G., Márquez, M., Pumarola, M. B., & Soto, C. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.815361 · Cited by 15
“Although tau aggregates can modulate Aβ toxicity, it has been reported that they are not able to induce Aβ aggregation (Bloom, 2014; Nisbet et al., 2015).”
BackgroundClinical Aspects of Alzheimer’s Disease
Kumfor, F., Halliday, G. M., & Piguet, O. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_2 · Cited by 21
Tau Protein Biosensors in the Diagnosis of Neurodegenerative Diseases
Sadeghzadeh, J., Shahabi, P., Farhoudi, M., Kalan, A. E., Mobed, A., & Shahpasand, K. (2022) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.061 · Cited by 18
Zhou, X., Kumar, P., Bhuyan, D. J., Jensen, S. O., Roberts, T. L., & Münch, G. W. (2023) · Biomolecules · doi:10.3390/biom13111568 · Cited by 17
“These protein deposits are thought to be part of pathological cascades, leading to neuronal dysfunction and cognitive decline [2].”
BackgroundDevi, M., & Paul, S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00387 · Cited by 15
Spreading of Pathology in Alzheimer’s Disease
Lv, Z., Tan, C., Yu, J., & Tan, L. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9765-2 · Cited by 18
“…effects of Aβ itself, the accumulation and subsequent deposition ofAβ could also lead to the phosphorylation and aggregation of Tau proteins in neurons and facilitate the propagation and toxicity of Tau inside neurons (Bilousova et al. 2016; Bloom 2014; Nisbet et al. 2015; Stancu etal.2014).”
Background
Metadata
- Authors
- Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J.
- Affiliations
- The University of Queensland (AU)
- UNSW Sydney (AU)
- Corresponding author
- Nisbet, Rebecca M.
- Götz, Jürgen
- Venue
- Acta Neuropathologica
- Published
- 2014-12-10
- Volume
- 129
- Issue
- 2
- Pages
- 207-220
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC4305093
- OpenAlex
- W2007787335
- Cited by
- 359
- References
- 114
- Citations by year
- 2026: 14 · 2025: 32 · 2024: 20 · 2023: 22 · 2022: 49 · 2021: 41 · 2020: 33 · 2019: 44 · 2018: 32 · 2017: 26 · 2016: 31 · 2015: 14
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Australian Research Council (DP13300101932)
- National Health and Medical Research Council (1003150, 1037746)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau aggregation, amyloid-beta, Alzheimer's disease, neurofibrillary tangles, amyloid plaques, tau oligomers, amyloid-beta oligomers, neurotoxicity, Fyn, immunotherapy, single-chain antibody, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Humans, Synapses, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.